Amikacin
Who holds supplier records for Amikacin? 1 organisation holds a current record for Amikacin: an active US FDA Type II Drug Master File. A further 1 organisation has only historical (inactive) DMF filings. Recorded organisation countries for current records: China (1).
Most records are filed under another form of this substance: Amikacin Sulfate (3 current sources). A DMF or CEP is listed under the form it names.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Amikacin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/amikacin
Reading the evidence
- One current record
One organisation holds a current DMF or CEP. A record shows a regulatory filing, not current commercial availability or a qualified source for your product.
- 1 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Amikacin expires 15 May 2035. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (1)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Amikacin. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Shandong Anxin Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 20874 · latest filing Sept 2007
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (1)
Organisations whose Type II DMFs for Amikacin are no longer active. These show a past filing, not current supply.
Show all 1 historical record
- Chongqing Daxin Pharmaceutical Co., Ltd.China · Inactive DMF 14007 · filed Mar 1999
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (8 listed products contain Amikacin). The latest listed patent expires 15 May 2035. The latest listed exclusivity runs to 28 Sept 2030. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Amikacin is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL177).
Chemical identity
- IUPAC name
- (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
- Canonical SMILES
- C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N
- InChIKey
- LKCWBDHBTVXHDL-RMDFUYIESA-N
- Synonyms
- Amikacin, Amikacina, Amikacine, Amikacinum, BAY 41-6551, Lukadin, NSC-177001, Potentox, CHEBI:2637, Amiklin, Biclin, Normon, Amikacina
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Aminoglycoside Antibacterial
- Chemical structure
- Aminoglycosides
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Amikacin?
1 organisation holds an active US FDA Type II Drug Master File or a CEP for Amikacin: Shandong Anxin Pharmaceutical Co., Ltd. (China). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Amikacin Drug Master Files are active?
Shandong Anxin Pharmaceutical Co., Ltd. (DMF 20874). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Amikacin records mean?
1 organisation has only inactive Type II DMFs for Amikacin. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Amikacin?
Yes. The latest patent listed for an approved US product containing Amikacin expires 15 May 2035, across 8 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Amikacin supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Amikacin?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.